• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    AirSculpt Technologies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    9/13/24 5:25:34 PM ET
    $AIRS
    Medical/Nursing Services
    Health Care
    Get the next $AIRS alert in real time by email
    false 0001870940 0001870940 2024-09-13 2024-09-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT 

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): September 13, 2024

     

    AirSculpt Technologies, Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

    Delaware

    (State or Other Jurisdiction

    of Incorporation)

    001-40973

    (Commission

    File Number)

    87-1471855

    (IRS Employer

    Identification No.)

         
    1111 Lincoln Road, Suite 802
    Miami Beach, Florida
     

     

    33139

    (Address of Principal Executive Offices)   (Zip Code)

     

    (786) 709-9690

    (Registrant’s Telephone Number, Including Area Code)

     

    Not applicable

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

     

    ¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of Each Class:   Trading
    Symbol(s):
     

    Name of Exchange
    on Which Registered:

    Common Stock, $0.001 par value per share   AIRS   The Nasdaq Global Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company x

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x

     

     

     

     

     

    Item 1.01 Entry into a Material Definitive Agreement.

     

    Amendment to Credit Agreement

     

    On September 13, 2024, AirSculpt Technologies, Inc., a Delaware corporation (the “Company”), EBS Intermediate Parent LLC, a Delaware limited liability company (“EBS Parent”), a wholly-owned subsidiary of the Company, EBS Enterprises LLC, a Delaware limited liability company (“Borrower”), a wholly-owned subsidiary of EBS Parent, and Silicon Valley Bank, a division of First-Citizens Bank & Trust Company (“SVB”), entered into a Second Amendment to Credit Agreement (the “Amendment”) in connection with that certain Credit Agreement, dated as of November 7, 2022 (as amended by that certain First Amendment and Limited Waiver to Credit Agreement, dated as of March 9, 2023, and as further amended, restated, supplemented or otherwise modified from time to time prior to the date hereof, the “Credit Agreement”), among the Company, EBS Parent, Borrower, the several banks and other financial institutions or entities from time to time party thereto (each a “Lender” and, collectively, the “Lenders”), and SVB as administrative agent and collateral agent for the Lenders, issuing lender and swingline lender, the form of which was attached as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission (the “SEC”) on November 9, 2022.

     

    Summary of the Material Terms and Conditions of the Amendment

     

    Under the terms of the Amendment, the parties thereto agreed to modify certain financial condition covenants made by the Company in the Credit Agreement, such that (i) the Consolidated Fixed Charge Coverage Ratio (as defined in the Credit Agreement) of the Company and its Subsidiaries as of the last day of the fiscal quarters ending December 31, 2024 and March 31, 2025 must be no less than 1.10:1.00 instead of 1.25:1.00, as previously set forth in the Credit Agreement; (ii) the Consolidated Leverage Ratio (as defined in the Credit Agreement) of the Company and its Subsidiaries as of the last day of the fiscal quarters ending September 30, 2024, December 31, 2024, March 31, 2025 and June 30, 2025 must not exceed 2.75:1.00, 3.25:1.00, 3.25:1.00, and 2.75:1.00, respectively, instead of 2.50:1.00, as previously set forth in the Credit Agreement; and (iii) the Company and its Subsidiaries will be required to maintain Liquidity (as defined in the Credit Agreement) no less than (A) $6,750,000.00 as of the last day of the fiscal quarter ending September 30, 2024, and (B) $7,500,000.00 as of the last day of the fiscal quarters ending December 31, 2024, March 31, 2025 and June 30, 2025.

     

    In connection with the modifications to the financial condition covenants relating to the Consolidated Leverage Ratio of the Company and its Subsidiaries, the parties to the Amendment also agreed to an increase in the interest rates per annum of the SOFR Loans, the ABR Loans, the Swingline Loans and the Letters of Credit (each as defined in the Credit Agreement) during the period beginning on September 13, 2024 and ending on or about June 30, 2025.

     

    Under the terms of the Amendment, the applicable margin for purposes of calculating the interest rate of SOFR Loans and ABR Loans during the period beginning on September 13, 2024 and ending on or about June 30, 2025 will be modified as follows: (i) if the Consolidated Leverage Ratio of the Company and its Subsidiaries is equal to or greater than 1.00:1.00 and less than 2.00:1.00, the applicable margin will increase from 1.50% for ABR Loans and 2.50% for SOFR Loans to 2.00% for ABR Loans and 3.00% for SOFR Loans, respectively; (ii) if the Consolidated Leverage Ratio of the Company and its Subsidiaries is equal to or greater than 2.00:1.00, the applicable margin will increase from 2.00% for ABR Loans and 3.00% for SOFR Loans to 2.50% for ABR Loans and 3.50% for SOFR Loans, respectively; and (iii) if the Consolidated Leverage Ratio of the Company and its Subsidiaries is below 1.00:1.00, the applicable margin will increase from 1.00% for ABR Loans and 2.00% for SOFR loans to 1.50% for ABR Loans and 2.50% for SOFR Loans, respectively.

     

    The applicable margin for purposes of calculating the interest rate of Swingline Loans during the period beginning on September 13, 2024 and ending on or about June 30, 2025 will be modified as follows: (i) if the Consolidated Leverage Ratio of the Company and its Subsidiaries is equal to or greater than 1.00:1.00 and less than 2.00:1.00, the applicable margin will increase from 1.50% to 2.00%; (ii) if the Consolidated Leverage Ratio of the Company and its Subsidiaries is equal to or greater than 2.00:1.00, the applicable margin will increase from 2.00% to 2.50%; and (iii) if the Consolidated Leverage Ratio of the Company and its Subsidiaries is below 1.00:1.00, the applicable margin will increase from 1.00% to 1.50%.

     

     

     

    The applicable margin for purposes of calculating the interest rate of any Letters of Credit during the period beginning on September 13, 2024 and ending on or about June 30, 2025 will be modified as follows: (i) if the Consolidated Leverage Ratio of the Company and its Subsidiaries is equal to or greater than 1.00:1.00 and less than 2.00:1.00, the applicable margin will increase from 2.50% to 3.00%; (ii) if the Consolidated Leverage Ratio of the Company and its Subsidiaries is equal to or greater than 2.00:1.00, the applicable margin will increase from 3.00% to 3.50%; and (iii) if the Consolidated Leverage Ratio of the Company and its Subsidiaries is below 1.00:1.00, the applicable margin will increase from 2.00% to 2.50%.

     

    In addition, each of the Company, EBS Parent and Borrower agreed to furnish to SVB within 45 days after the end of each calendar month a “key performance indicator” report, which will include month-end Unrestricted Cash (as defined in the Credit Agreement) and number of cases per facility, commencing with the calendar month ending July 31, 2024 and ending with the calendar month ending June 30, 2025.

     

    The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Amendment, which is filed as Exhibit 10.1 to this Current Report on Form 8-K, and is incorporated into this Item 1.01 by reference.

     

    Item 9.01. Financial Statements and Exhibits.

     

    (d)Exhibits

     

    Exhibit No. Description
    10.1 Second Amendment to Credit Agreement, dated September 13, 2024
    104  Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Dated: September 13, 2024  
       
      AirSculpt Technologies, Inc.
       
      By: /s/ Dennis Dean
        Name: Dennis Dean
        Title: Interim Chief Executive Officer and Chief Financial Officer

     

    [Signature Page to the Form 8-K]

     

     

     

    Get the next $AIRS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AIRS

    DatePrice TargetRatingAnalyst
    10/17/2024Neutral
    BTIG Research
    5/14/2024$8.25 → $5.00Outperform → Market Perform
    Leerink Partners
    11/11/2022$4.00Overweight → Neutral
    Piper Sandler
    6/16/2022$17.00 → $8.50Overweight → Equal-Weight
    Morgan Stanley
    11/23/2021$18.00Outperform
    Raymond James
    11/23/2021$17.00Overweight
    Morgan Stanley
    11/23/2021$26.00Outperform
    SVB Leerink
    11/23/2021$22.00Overweight
    Piper Sandler
    More analyst ratings

    $AIRS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Jashnani Yogesh covered exercise/tax liability with 24,217 shares, decreasing direct ownership by 5% to 496,759 units (SEC Form 4)

    4 - Airsculpt Technologies, Inc. (0001870940) (Issuer)

    2/5/26 5:45:00 PM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    Chief Financial Officer Arthur Michael J was granted 147,059 shares (SEC Form 4)

    4 - Airsculpt Technologies, Inc. (0001870940) (Issuer)

    1/27/26 4:30:15 PM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    SEC Form 3 filed by new insider Arthur Michael J

    3 - Airsculpt Technologies, Inc. (0001870940) (Issuer)

    1/15/26 5:00:10 PM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    $AIRS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    AirSculpt Technologies Appoints Mike Doyle as Non-Executive Chairman of the Board

    MIAMI BEACH, Fla., Nov. 17, 2025 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (NASDAQ:AIRS)("AirSculpt" or the "Company"), a national provider of premium body contouring procedures, today announced the appointment of Mike Doyle as the Non-Executive Chairman of its Board of Directors. Mr. Doyle brings over 30 years of leadership experience in the multi-center healthcare sector. He also serves on several boards where he is recognized for both operating experience and strategic expertise. Yogi Jashnani, CEO of AirSculpt, commented, "Mike has helped to build several successful multi-site healthcare organizations with great experience partnering with surgeons while developing new centers

    11/17/25 5:32:51 PM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    AirSculpt Technologies Reports Third Quarter Fiscal 2025 Results

    MIAMI BEACH, Fla., Nov. 07, 2025 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (NASDAQ:AIRS)("AirSculpt" or the "Company"), a national provider of premium body contouring procedures, today announced results for the third quarter ended September 30, 2025. Yogi Jashnani, Chief Executive Officer, stated: "During the quarter, we made strong progress on our key initiatives that focused on new growth opportunities, margin improvement, and debt reduction. While third quarter revenue was lower than anticipated, this is reflective of timing, instead of the trajectory of our business. We see a broader market opportunity ahead driven by the structural shift in the aesthetics space due to GLP-1 us

    11/7/25 6:00:00 AM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    AirSculpt Technologies Announces Third Quarter Fiscal 2025 Earnings Release Date and Conference Call

    MIAMI BEACH, Fla., Oct. 31, 2025 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. ("AirSculpt") (NASDAQ:AIRS) an industry leader and provider of premium body contouring procedures, today announced it will report third quarter 2025 financial results before market open on Friday, November 7, 2025, to be followed by a conference call on the same day at 8:30 a.m. Eastern Time. The conference call can be accessed by dialing 1-877-407-9716 (toll-free domestic) or 1-201-493-6779 (international) using the conference ID 13756042 or by clicking this link to request a return call for instant telephone access to the event. The live webcast may be accessed via the investor relations section of the Air

    10/31/25 6:45:00 AM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    $AIRS
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by AirSculpt Technologies Inc.

    SCHEDULE 13G/A - Airsculpt Technologies, Inc. (0001870940) (Subject)

    2/13/26 6:44:35 PM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by AirSculpt Technologies Inc.

    SCHEDULE 13G/A - Airsculpt Technologies, Inc. (0001870940) (Subject)

    11/14/25 6:07:40 PM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    SEC Form 10-Q filed by AirSculpt Technologies Inc.

    10-Q - Airsculpt Technologies, Inc. (0001870940) (Filer)

    11/7/25 4:37:23 PM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    $AIRS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Feinstein Adam T bought $4,000,000 worth of shares (1,000,000 units at $4.00) (SEC Form 4)

    4 - Airsculpt Technologies, Inc. (0001870940) (Issuer)

    6/11/25 5:06:44 PM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    Executive Chairman Rollins Aaron bought $7,629 worth of shares (2,118 units at $3.60), increasing direct ownership by 0.01% to 15,146,039 units (SEC Form 4)

    4 - Airsculpt Technologies, Inc. (0001870940) (Issuer)

    5/20/25 4:11:19 PM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    Chief Executive Officer Jashnani Yogesh bought $18,532 worth of shares (7,000 units at $2.65), increasing direct ownership by 2% to 464,879 units (SEC Form 4)

    4 - Airsculpt Technologies, Inc. (0001870940) (Issuer)

    5/7/25 5:56:15 PM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    $AIRS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BTIG Research initiated coverage on AirSculpt Technologies

    BTIG Research initiated coverage of AirSculpt Technologies with a rating of Neutral

    10/17/24 7:13:51 AM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    AirSculpt Technologies downgraded by Leerink Partners with a new price target

    Leerink Partners downgraded AirSculpt Technologies from Outperform to Market Perform and set a new price target of $5.00 from $8.25 previously

    5/14/24 7:53:44 AM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    AirSculpt Technologies downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded AirSculpt Technologies from Overweight to Neutral and set a new price target of $4.00

    11/11/22 3:44:11 PM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    $AIRS
    Leadership Updates

    Live Leadership Updates

    View All

    AirSculpt Technologies Names Yogi Jashnani Chief Executive Officer

    MIAMI BEACH, Fla., Dec. 17, 2024 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (NASDAQ:AIRS) ("AirSculpt" or the "Company"), an industry leader and provider of premium body contouring procedures, today announced the appointment of Yogi Jashnani as Chief Executive Officer ("CEO") and a member of the Board of Directors. He succeeds Dennis Dean, Interim Chief Executive Officer and Chief Financial Officer who will continue as Chief Financial Officer, all effective January 7, 2025. A highly-talented, results oriented executive with an accomplished career spanning more than two decades, Mr. Jashnani has architected successful transformations for public and private companies in the aesthetics

    12/17/24 6:45:00 AM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    $AIRS
    Financials

    Live finance-specific insights

    View All

    AirSculpt Technologies Reports Third Quarter Fiscal 2025 Results

    MIAMI BEACH, Fla., Nov. 07, 2025 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (NASDAQ:AIRS)("AirSculpt" or the "Company"), a national provider of premium body contouring procedures, today announced results for the third quarter ended September 30, 2025. Yogi Jashnani, Chief Executive Officer, stated: "During the quarter, we made strong progress on our key initiatives that focused on new growth opportunities, margin improvement, and debt reduction. While third quarter revenue was lower than anticipated, this is reflective of timing, instead of the trajectory of our business. We see a broader market opportunity ahead driven by the structural shift in the aesthetics space due to GLP-1 us

    11/7/25 6:00:00 AM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    AirSculpt Technologies Announces Third Quarter Fiscal 2025 Earnings Release Date and Conference Call

    MIAMI BEACH, Fla., Oct. 31, 2025 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. ("AirSculpt") (NASDAQ:AIRS) an industry leader and provider of premium body contouring procedures, today announced it will report third quarter 2025 financial results before market open on Friday, November 7, 2025, to be followed by a conference call on the same day at 8:30 a.m. Eastern Time. The conference call can be accessed by dialing 1-877-407-9716 (toll-free domestic) or 1-201-493-6779 (international) using the conference ID 13756042 or by clicking this link to request a return call for instant telephone access to the event. The live webcast may be accessed via the investor relations section of the Air

    10/31/25 6:45:00 AM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    AirSculpt Technologies Announces Second Quarter Fiscal 2025 Earnings Release Date and Conference Call

    MIAMI BEACH, Fla., July 25, 2025 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. ("AirSculpt") (NASDAQ:AIRS), an industry leader and provider of premium body contouring procedures, today announced it will report second quarter 2025 financial results before market open on Friday, August 1, 2025, to be followed by a conference call on the same day at 8:30 a.m. Eastern Time. The conference call can be accessed by dialing 1-877-407-9716 (toll-free domestic) or 1-201-493-6779 (international) using the conference ID 13754561 or by clicking this link to request a return call for instant telephone access to the event. The live webcast may be accessed via the investor relations section of the Air

    7/25/25 6:45:00 AM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    $AIRS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by AirSculpt Technologies Inc.

    SC 13G/A - Airsculpt Technologies, Inc. (0001870940) (Subject)

    11/8/24 8:42:05 PM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    SEC Form SC 13G/A filed by AirSculpt Technologies Inc. (Amendment)

    SC 13G/A - Airsculpt Technologies, Inc. (0001870940) (Subject)

    2/14/24 1:11:48 PM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    SEC Form SC 13G filed by AirSculpt Technologies Inc.

    SC 13G - Airsculpt Technologies, Inc. (0001870940) (Subject)

    4/27/23 9:49:49 PM ET
    $AIRS
    Medical/Nursing Services
    Health Care